Intervene Immune
CompanyUnited States
Intervene Immune develops one asset, in phase 2 (TRIIM Treatment in epigenetic aging). Mostly other acting on epigenetic regulation of gene expression and cellular senescence; based in the United States.
- 1
- Asset
- Furthest
- Phase 2
- Raised
- US$470.8k
- 1
- Grant
- 1
- Trial
- 0
- Signals
Pipeline
1Regimen of recombinant human growth hormone, DHEA, and metformin for thymus regeneration
Phase 2, Other, Epigenetic regulation of gene expression, Cellular senescence, epigenetic aging, immunosenescence
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Funding rounds and grants1
- People2
- Similar companies6
Updated 10 Oct 2026 · 5 sources